Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health Chief Information Officer Kumud Kalia reported routine stock-based compensation activity. On June 15, 2026, 638 restricted stock units converted into common shares, while 314 shares were withheld by the company to cover tax obligations. After these transactions, Kalia directly holds 41,414 common shares.
Guardant Health director Tariq Musa reported a small mix of stock transactions involving company shares. On June 15, 2026, a restricted stock unit (RSU) award converted into 250 shares of common stock at a stated price of $0.00 per share, reflecting vesting of previously granted equity compensation.
The same RSU award was originally granted on March 6, 2023 and vests over four years, with 25% vesting on March 15, 2024 and the remaining 75% vesting monthly over three years. On June 16, 2026, Musa executed an open-market sale of 116 shares of common stock at an average price of $130.19 per share. Following these transactions, he holds 8,796 shares of Guardant Health common stock directly.
Guardant Health Chief Legal Officer John G. Saia reported compensation-related stock activity on June 15, 2026. He exercised 1,020 restricted stock units into common shares, then had 535 of those shares withheld by the company at $129.82 per share to cover tax obligations, with no open-market sale. After these transactions, Saia directly holds 36,435 Guardant Health shares. The RSU award was granted on June 9, 2023 and vests over three years, with 33% vesting on June 15, 2024 and the remaining 67% vesting in equal quarterly installments over the following two years.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported routine equity compensation activity involving restricted stock units and common stock. On June 15, 2026, 1,402 restricted stock units were converted into an equal number of common shares as part of a previously granted award that vested over a three-year period.
To cover related tax obligations on this vesting, the company retained 594 common shares at a price of $129.82 per share, a non-market tax-withholding disposition rather than an open-market sale. Following these transactions, Freeman directly held 61,101 common shares of Guardant Health.
Guardant Health, Inc.’s Chief Financial Officer Michael Brian Bell reported routine equity compensation activity. On June 15, 2026, 2,039 Restricted Stock Units were converted into an equal number of shares of common stock, reflecting the vesting schedule of an award granted on June 9, 2023.
On the same date, 1,096 shares of common stock were withheld by the company to cover Mr. Bell’s tax withholding obligations tied to this vesting, with the shares valued at $129.82 each. After these transactions, Mr. Bell directly owned 48,452 shares of Guardant Health common stock.
Guardant Health (GH) notice of proposed insider sales by Musa Tariq. The filing lists prior sales of common stock in three separate transactions: 03/18/2026 — 348 shares (aggregate $30,655), 04/16/2026 — 116 shares (aggregate $9,840), and 05/18/2026 — 116 shares (aggregate $11,131).
The filing also records a restricted stock lapse on 06/15/2026 associated with equity compensation and lists brokerage details for Charles Schwab & Co. The notice records proposed sale activity under Form 144; timing and method of any future sales are not detailed beyond the listed items.
Guardant Health, Inc. Chief Information Officer Kumud Kalia reported an open-market sale of 3,418 shares of Common Stock on June 11, 2026 at an average price of $130.2386 per share. After this transaction, Kalia directly holds 41,090 shares, indicating he retains a substantial ongoing equity stake.
GH affiliate reported a proposed sale of 5,000 shares of Common Stock by Kumud Kalia on 06/10/2026, with a reported gross value of $652,030.00. The filing lists prior open-market purchases of 2,231 shares on 06/09/2023 and 2,187 shares on 03/18/2024.
GH affiliate filing amends a prior Form 144. The filing reports a sale of 5,000 shares on 06/10/2026 for $652,030 and lists 600 shares purchased on 06/09/2023 via open-market purchase. The broker on record is Fidelity Brokerage Services LLC.
Form 144 notice of proposed sales by Kumud Kalia and a prior purchase record. The filing lists sales by Kumud Kalia of 6,839 shares on 03/15/2026 for $584,666.00, 5,092 shares on 04/01/2026 for $464,135.80, and 5,000 shares on 06/10/2026 for $652,030.00. The record also shows Fidelity Brokerage Services LLC purchased 600 shares in an open-market purchase on 06/09/2023.